

EUPATI Sustaining Partners 2025

Sustaining Partner eligibility criteria:

To be part of the SPA, a partner needs to have committed substantially to the continuation of EUPATI through contributing in-cash or in-kind to the EUPATI 2025 Programme and beyond. All currently existing National Platforms are also considered as Sustaining Partners.

List of EUPATI 2024 Sustaining Partners:

Industry	Patient Organisations	Academia/Non-Profit	National Platforms
Abbvie	Digestive Cancers Europe (DiCE)	Drug Information Association (DIA)	Austria
Almirall	European AIDS Treatment Group (EATG)	European Infrastructure for Translational Medicine (EATRIS)	Belgium
Amgen	European Federation of Allergy and Airways Diseases Patients' Associations (EFA)	European Clinical Research Infrastructure Network (ECRIN)	Czech Republic
AstraZeneca	European Liver Patients' Association (ELPA)	European Forum for Good Clinical Practice (EFGCP)	Cyprus
Bayer	European Patients' Forum (EPF)	European Organisation for Research and Treatment of Cancer (EORTC)	Denmark
Boehringer Ingelheim	Global Heart Hub (GHH)	FindMeCure Foundation	Finland
Chiesi	Parkinson's Europe	ISPOR	France
CSL Behring	SMA Europe	INNODIA	Germany
Daiichi Sankyo	The International Alliance of Dermatology Patient Organizations (GlobalSkin)	KU Leuven	Greece
Gilead	The Irish Platform for Patient Organisations, Science and Industry (IPPOSI)	Sant Joan de Deu Research Institute	Ireland
Greenphire		The Organisation for Professionals in Regulatory Affairs (TOPRA)	Italy
GlaxoSmithKline		South East Technological University (SETU)	Japan
Incyte		University College Dublin	Luxembourg
Janssen		Vall d'Hebron University Hospital	Malta
Lundbeck			Netherlands
Menarini			Norway
MSD			Poland
Novartis			Portugal
Novocure			Scotland
Pfizer			Slovakia
Roche			Spain
Servier			Sweden
Sobi			Switzerland
Takeda			Turkey
UCB			
ViiV Healthcare			